Carl Regillo, MD, Thomas Jefferson University School of Medicine

Carl Regillo, MD and Diana Do, MD react to newer therapies being explored for wet AMD and discuss their place in future therapeutic algorithms.

An overview of new gene therapy options for wet AMD that are currently being explored in clinical trials.

Results of recent phase III clinical trials with respect to efficacy and safety of faricimab, an investigational bispecific antibody which inhibits both VEGF-A and angiopoietin-2.   

Retina specialists provide insight into the patient selection and safety concerns with the innovative Port Delivery System (PDS) that offers a new means of sustained anti-VEGF therapy.

Carl Regillo, MD highlights the Port Delivery System (PDS), a new surgical implant with sustained release of anti-VEGF therapy that recently completed phase III clinical trials.

Carl Regillo, MD and Diana Do, MD discuss the safety concerns with the use of brolucizumab in wet AMD and the impact of these concerns in their practice.

An overview of standard anti-VEGF treatments for wet AMD and recommendations for individualizing patient therapy with a treat and extend approach.

Role of imaging modalities in the diagnosis and monitoring of age-related macular degeneration (AMD).

Carl Regillo, MD and Diana Do, MD, describe the progressive nature of age-related macular degeneration (AMD) and differences between dry AMD and wet AMD.